C. Ernest

发表

Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes

M. Trautmann, P. Kothare, H. Linnebjerg, 2006, Diabetic medicine : a journal of the British Diabetic Association.

Benefits of Non-Linear Mixed Effect Modeling and Optimal Design : Pre-Clinical and Clinical Study Applications

C. Ernest, 2013 .

BASED INACTIVATION OF CYTOCHROME P 450 3 A ( CYP 3 A ) BY HIV PROTEASE INHIBITORSa

C. Ernest, S. Hall, David R. Jones, 2004 .

Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis

L. Tham, C. Ernest, W. Macias, 2017, CPT: pharmacometrics & systems pharmacology.

Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38

E. Antman, E. Braunwald, S. Wiviott, 2009, Journal of clinical pharmacology.

Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease

L. Wallentin, K. Winters, C. Ernest, 2008, Journal of Pharmacokinetics and Pharmacodynamics.

Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects

K. Winters, C. Ernest, J. Jakubowski, 2008, Pharmacotherapy.

Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy

Junxiang Luo, C. Ernest, R. Wrishko, 2012, Journal of clinical pharmacology.

Integrated Analysis of Pharmacokinetic Data Across Multiple Clinical Pharmacology Studies of Prasugrel, a New Thienopyridine Antiplatelet Agent

K. Winters, C. Ernest, N. Farid, 2011, Journal of clinical pharmacology.

Abstract 4001: Relationship between Exposure to the Prasugrel Active Metabolite with TIMI Major/Minor Bleeding in TRITON-TIMI 38

E. Antman, S. Wiviott, C. Ernest, 2008 .

Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in Humans

K. Winters, C. Ernest, N. Farid, 2008, Journal of clinical pharmacology.

Prediction of Prasugrel Active Metabolite Concentrations From 2 Downstream Inactive Metabolite Concentrations Using Multilinear Regression Analysis

M. Heathman, C. Ernest, R. Wrishko, 2009, Journal of clinical pharmacology.

Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing

K. Winters, C. Ernest, R. Wrishko, 2009, Drugs & aging.

Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects

K. Winters, C. Ernest, J. Jakubowski, 2009, Current medical research and opinion.

Mechanism-Based Inactivation of CYP 3 A by HIV Protease Inhibitors

C. Ernest, S. Hall, David R. Jones, 2005 .

Inhaled micronized crystalline human insulin using a dry powder inhaler: dose‐response and time‐action profiles 1

L. Heinemann, K. Rave, L. Nosek, 2004, Diabetic medicine : a journal of the British Diabetic Association.

Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC).

F. Cappuzzo, E. Smit, D. Ferry, 2015 .

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

S. Iturria, K. Winters, C. Ernest, 2007, Journal of thrombosis and haemostasis : JTH.

Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors

C. Ernest, S. Hall, David R. Jones, 2005, Journal of Pharmacology and Experimental Therapeutics.

Methodological Comparison of In Vitro Binding Parameter Estimation: Sequential vs. Simultaneous Non-linear Regression

Andrew C. Hooker, Mats O. Karlsson, C. Steven Ernest, 2010, Pharmaceutical Research.

Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

K. Winters, C. Ernest, J. Jakubowski, 2007, Clinical pharmacology and therapeutics.

Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel

K. Winters, C. Ernest, J. Jakubowski, 2007, Journal of cardiovascular pharmacology.

STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE

Jenny Y Chien, S. Wrighton, J. Chien, 2006, Drug Metabolism and Disposition.

Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro.

L. Heinemann, K. Rave, L. Nosek, 2005, Diabetes care.

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

C. Ernest, S. Shcherbinin, B. Willis, 2023, Clinical pharmacology and therapeutics.

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

C. Ernest, S. Shcherbinin, B. Willis, 2023, Alzheimer's & dementia.

Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics

C. Ernest, J. Sauer, H. Thomasson, 2002, Journal of clinical pharmacology.

Multinomial Markov-chain model of sleep architecture in Phase Advanced Subjects

Andrew C. Hooker, Mats O. Karlsson, David J. DeBrota, 2013 .

Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model

Andrew C. Hooker, Mats O. Karlsson, Joakim Nyberg, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end‐stage renal disease

K. Winters, C. Ernest, R. Wrishko, 2009, Journal of clinical pharmacy and therapeutics.

Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro.

L. Heinemann, K. Rave, L. Nosek, 2005, Diabetes care.

PK/PD modeling links accelerated resolution of COVID‐19‐related clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together

J. Chien, C. Ernest, E. Chigutsa, 2022, CPT: pharmacometrics & systems pharmacology.

Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease

K. Winters, C. Ernest, N. Farid, 2009, Journal of clinical pharmacy and therapeutics.